Compositions for delivering perfume to the skin.

(54) Title: COMPOSITIONS TO SUPPLY PERFUME TO THE SKIN. (54) Title: COMPOSITIONS FOR DELIVERING PERFUME TO THE SKIN.

(57) Summary

A cleaning composition comprising at least 5% of a surfactant, at least about 25% water, a cyclodextrin complex comprising a perfume, wherein 80% of the plurality of perfume raw materials comprises a FDV of at least 0.69.

(57) Abstract

A cleansing composition comprising at least 5% of a surfactant, at least about 25% water, a cyclodextrin complex comprising a perfume, where 80% of the plurality of perfume raw materials comprise a FDV of at least 0.69.

HE «CRRtó Oi KX.1MMÍÁ \> '^-'-\^

Institute

Mexican Property

Industrial

<img file="MX339063B_D0001.tif" />

PATENT TITLE ΝΟΓ339063

Owner (s): THE PROCTER &amp; GAMBLE COMPANY

Address: One Procter &amp; Gamble Plaza, Cincinnatl, Ohió, 45202, USA

Name: COMPOSITIONS TO SUPPLY PERFUME TO THE SKIN.

Classification: lnt.CI.8: A61K31 / 555; A61K8 / 46; A61K8 / 73; A61Q13 / 00; A61Q19 / 10; A61Q5 / 02

Inventors): TIMOTHY ALAN SCAVONE; JIANJUN JUSTIN LI; MARC ADAM FLICKINGER;

JONATHAN ROBERT CETTI

Number:

MX / a / 2014/011366

Country:

US

REQUEST

International filing date:

March 2013

PRIORITY

Date:

March 2012

TI '' ShS'i:

Number:

13/428,347

Validity: Twenty years roof of Venciúiienti: March 21, 2033 Ί

The reference patent is granted on the basis of all articles 1, 2, section V, 6, section III, and 59 of the Industrial Property Law.

In accordance with article 23 of the Law of the PropMatf MuaMak, this patent has a validity of twenty years, not applicable, indented from the date of filing of the sonetead -MaraKianal and will be subject to the payment of the fee to maintain the rights . , ·: = '· :::' '

Whoever subscribes to this title does so based on the provisions of articles V sections III and 7a bis 2 of the Law of (Industrial Type (Official Gazette of the Federation (DOF) 06/27/1991. amended on 08/02/1994, 10/25/1996, 12/26/1997, 05/17/1999, i | / 01/2004, 06/16/2005, 251) 1/2006, «/ 05/2009 , 01/06/2010, 08/18/2010, 06/28/2010, 01/27/2012 and 04/09/2012), articles 1 », 3“ fraction V, subsection a), subsection Iii) 4th ί | 12th sections I and III of the Regulations of the Mateean Institute of Industrial Property (DOF 14/12/1999, reported on 07/01/2002, 1 ¡§67 / 2004, 07/26/2004 and 09/07/2007) ; 1st articles. 3rd, 4th, 5th fraction V subsection a), sub subsection II), 16 fraction I and III and «j of the JSSttriP. OfrttoieeAl InstltutSjMeidsaflS.fijp. to Industrial Property (DQF 12/27/1999. amended «1 10/10/2002, 29/97/2004, 04Λ) ®2ββ4 and * TS / 0OTWT (;“ T °, ​​3 ° and s'InctSo'aTy antepenultimate par of the Agreement that détéga faetiltádes in the Deputy Directors General , Coordinator, Divisional Directors, Head of the Regional Offices, Divisional Deputy Directors, Departmental Coordinators and other subordinates of the Mexican Institute of Industrial Property. (DOF 12/15/1999, amended on 02/04/2000, 07/29/2004, 08/04/2004 and 09/13/2007).

<img file="MX339063B_D0002.tif" />

Issue Date: May 6, 2016

DIVISIONAL EXAMINATION OF PATENT FUND, ELECTRICAL AREAS AND INDUSTRIAL DESIGN REGISTRIES AND

<img file="MX339063B_D0003.tif" />

<img file="MX339063B_D0004.tif" />

Sand! No. 550, Floor i.

Coi Pueblo Sania María Tepepan,

Xochímilco, CP 16050,

Mexico City

Tel (55) 53 34 07 00 www.impjqob.mx

MX / 2016/36542

COMPOSITIONS TO SUPPLY PERF

QMÉfoM'ig-I

MEXICAN INSTITUTE OF PROPERTY

INDUSTRIAL

<img file="MX339063B_D0005.tif" />

BACKGROUND OF THE INVENTION5 Cleaning the skin is an activity that has been done for millennia.

Over time, skin cleansing and related skin cleansing methods involved the use of soap, surfactants, and the like. Today, a predominant form of skin cleansing compositions is the liquid form that is often known as liquid body soap. Liquid soap users enjoy the conveniences offered by these compositions; however experience is not ideal. Skin cleansing compositions have evolved, the problems associated with these compositions have not. Many of the problems associated with current skin cleansing compositions and methods, particularly liquid body soap compositions, have not been addressed and remain an issue for users of these products today.

Perfumes are frequently associated with liquid body soaps. These perfumes perform a number of tasks. Perfumes within a liquid body soap composition cover and / or mask the odor of a liquid body soap composition with a scent that pleases the user. The perfumes in a composition of liquid soap for the body Also indicate the effectiveness of the product to a user. Additionally, perfumes within a liquid body soap composition are supplied in very small amounts to the skin.

While perfumes within a liquid body soap are supplied to the skin, the delivery of these compositions runs poorly. Most of the perfume within the composition denjeBoaAiefu ΐΝηιιςτι 'IEDAD INDUSTRIAL

<img file="MX339063B_D0006.tif" />

The body is rinsed during the user's cleansing, leaving little perfume deposited on the skin to provide a benefit to the user. Furthermore, the benefit to the user of this perfume reservoir is not maximized, since the release of these materials begins immediately after the reservoir, probably while the user is still fresh from the associated cleaning.

Therefore, there is a need to provide a liquid body soap with a longer lasting perfume composition. Specifically, there is a need to provide a liquid body soap with a perfume composition that deposits, more effectively, and is capable of lasting beyond the user's initial cleaning. This invention addresses these needs.

BRIEF DESCRIPTION OF THE INVENTION

In one embodiment, there is a cleaning composition comprising at least 5% of a surfactant, at least about 25% water, a cyclodextrin compound comprising a plurality of perfume raw materials, at least one is selected from Iso-E Super, methyl ionone, α -rona, gamma methyl ionone, Labienone Oxim, cashmeran, delta-damascone, beta-ionone, dihydro-beta-ionone, damascenone, trans and alfadamascone where 80% of the plurality of perfume raw materials comprise a FDV of at least 0.70. In an alternate embodiment, there is a cleansing composition for supplying a dilution caused by the release of a perfume comprising: at least 5% of a surfactant, at least about 25% water a cyclodextrin complex comprising a perfume, said perfume which includes raw material,

<img file="MX339063B_D0007.tif" />

minus one comprises a FDV of at least about 0.

Water to cyclodextrin complex is among approximately cleaning composition comprising an ARDON value of 31 minus 130%. Still in another embodiment, there is a cleaning composition comprising at least 5% of a surfactant, at least about 25% water, a cyclodextrin complex comprising a perfume, the perfume comprising a plurality of perfume raw materials, at least one of these is selected Iso-E Super, methyl ionone, a-irone, gamma methyl ionone, Labienone Oxim, Cashmeran, delta-damascone, beta-ionone, dihydro-beta-ionone, damascenone, trans and alpha-damascone, wherein 80% of the plurality of perfume raw materials comprise a FDV of at least 0.70, where the ratio of water to cyclodextrin complex is between about 15: 1 and 1: 1, where the cleaning composition comprises a ARDON value of at least 130%. In yet another embodiment, there is a cleaning composition comprising: at least 5% of a surfactant, at least about 25% water, a cyclodextrin complex comprising a perfume, the perfume comprises a plurality of perfume raw materials, at least one of these is selected from iso-E Super, methyl ionone, a-irone, gamma methyl ionone, Labienone Oxim, Cashmeran, delta-damascone, beta-ionone, dihydro-beta-ionone, damascenone, trans- and alphadamascone, wherein the cyclodextrin complex has a degree of complex formation of at least 90% prior to incorporation into the cleaning composition.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a graph illustrating dilution relative to laminar volume.

DETAILED DESCRIPTION OF INVENClthÍVÍ PT Mexican Institute

OF THE PROPERTY &lt;

IN D'JSTRIaL

The dimensions and values ​​described in the ~ present description are not— to be understood as strictly limited to the exact numerical values ​​mentioned. Instead, unless otherwise specified, each of those dimensions will refer to both the mentioned value and a functionally equivalent range comprising that value. For example, a dimension expressed as "40mm" will be understood as "approximately 40mm".

All documents cited in the Detailed Description of the Invention section are incorporated, in the relevant part, by reference in the present description.

The citation of any document should not be construed as an admission that it represents a prior matter with respect to the present invention. To the extent that any meaning or definition of a term in this written document contradicts any meaning or definition of the term in a document incorporated by reference, the meaning or definition assigned to the term in this written document shall govern.

Although the specification concludes with the claims which particularly point to and clearly claim the invention, it is believed that the present invention will be better understood from the following description.

The devices, apparatus, methods, components, and compositions of the present invention may include, consist practically of, or consist of the components of the present invention and also of other ingredients described in the present description. As used herein, "consisting of virtually" means that the devices, apparatus, methods, components, or compositions may include Additional Ingredients, but only if the Additional Ingredients do not materially alter the basic and novel characteristics of the

<img file="MX339063B_D0008.tif" />

devices, apparatus, methods, components or compositions rei

All the percentages and proportions used were erila.

expressed by weight of the total composition; all mpriit; inn &lt;is sfi malleada at 25 ° C. unless otherwise indicated.

All measurements used in the present invention are expressed in metric units, unless otherwise specified.

The term "anhydrous", as used in the present description and unless otherwise specified, refers to compositions or materials containing less than about 10%, more preferably, less than about 5%, even more preferably , less than about 3%, even more preferably, zero percent, by weight of water.

The term "multiphase" as used in the present description means that the compositions comprise at least two phases that are chemically different (eg, a surfactant phase and a beneficial phase). These phases are in direct physical contact with each other and are not separated by a barrier. In one aspect of the invention, the personal care composition may be a multiphase personal care composition, where the phases of the personal care composition are combined or mixed to a significant degree. In another aspect of the invention, the personal care composition may be a multiphase personal care composition where the phases of the personal care composition are made to occupy separate but physically distinct spaces within the packaging in which they are stored, but they are in direct physical contact with each other, (that is, they are not separated by a physical barrier and they do not emulsify or mix with each other to any significant degree).

The term "packaging" includes any suitable packaging for personal care compositions that exhibit a viscosity of from about 1,500 centipoise (cP) to about 1,000,000 cP, which includes, but are not limited to, bottle, invert packaging, tube, frasc ^ sTpombáicSin

OF THE INDUSTRIAL FROHEDAD mixtures of these.

As used herein, the term "personal care composition" refers to compositions useful for topical application to the skin or hair. The compositions of the present invention are rinse-off formulations, which means that the product is applied topically to the skin or hair and after a few minutes it is rinsed from the skin or hair, with water, or cleaned of any other way by using a substrate that has a deposit of a portion of the composition. The compositions can also be used as shaving aids. The personal care composition of the present invention is typically extrudable or disposable from a package. Multiphase personal care compositions typically show a viscosity of about 1,500 centipoise (cP) to about 1,000,000 cP, as measured by the viscosity test method as described in the joint property patent application published Nov. 11, 2004 under no. of publication in the USA USA 2004 / 0223991A1 entitled "Multiphase Compositions for Personal Care" presented on May 7, 2004 by Wei, et al. The multiphase personal care compositions of the present invention may be in the form of liquid, semi-liquid, cream, lotion or gel compositions intended for topical application to the skin. Examples of personal care compositions of the present invention may include, but are not limited to, shampoo, conditioning shampoo, liquid body soap, moisturizing liquid body soap, shower gels, skin cleansers, cleansing milks , liquid hair and body soap, body moisturizer, pet shampoo, shaving preparations and cleansing compositions used in conjunction with a cleansing fabric

Ί disposable.

The phrase “substantially free of” as^wen- * ia

INSTITUTO MCXIO.NÓ DE IA IROPIEDAO. . . ,,. , industrial -. .

description, unless otherwise specified means that the composition

<img file="MX339063B_D0009.tif" />

it comprises less than about 5%, preferably, less than and about 3%, more preferably less than about 1% and most preferably less than about 0.1% of the designated ingredient. As used in the present description, the expression "free of" means that the composition comprises 0% of the mentioned ingredient, that is, the ingredient has not been added to the composition, however, these ingredients may be incidentally formed as a by-product or product reaction of the other components of the composition.

The term "stable" as used in the present description means that the multiphase personal care composition comprises less than 10% of the volume of the "third phase", more preferably less than 5% of the volume of the "third phase" third phase ”, most preferably, less than 1% of the volume of the“ third phase ”after undergoing the rapid aging protocol and measurement of the third phase as described below in the“ third phase ”method .

The term "structured", as used in the present description, means that it has a rheology that confers stability in the multiphase composition. The degree of structure is determined by the characteristics determined by one or more of the following methods: the Young's Modulus method, the yield strength method, or the zero shear viscosity method or by the ultracentrifuge method, all in the test methods below. Accordingly, a surfactant phase of the multiphase composition of the present invention is considered to be "structured," if the surfactant phase has one or more of the following properties, described below, in accordance with the Young's Modulus method, the creep limit method, the métcfioTtaáTví

<img file="MX339063B_D0010.tif" />

INSTITUTO MEXICANO shear zero, or the ultracentrifugation method. It is considered that; a structured phase ^^^ &amp; tpnt if the phase has one or more of the following characteristics:

A. A zero shear viscosity of at least about 100

<td colspan="2">Pascal for seconds (Pa-s),</td><td>alternatively,</td><td>to the</td><td>less</td>

<td>approximately</td><td>200 Pa-s,</td><td>alternatively,</td><td>to the</td><td>less</td>

<td>approximately</td><td>500 Pa-s,</td><td>alternatively,</td><td>to the</td><td>less</td>

<td>approximately</td><td>1,500 Pa-s,</td><td>alternatively,</td><td>to the</td><td>less</td>

<td colspan="2">approximately 2,000 Pa-s; or</td><td></td><td></td><td></td>

B. A structured domain volume ratio measured by the ultracentrifugation method, described below, greater than about 40%, preferably, at least about 45%, more preferably, at least about 50%, more preferably, at least about 55%, more preferably, at least about 60%, more preferably, when

<td colspan="6">less about 65%, more preferably at least</td>

<td>approximately</td><td> 70 %,</td><td>with</td><td>higher preference,</td><td>to the</td><td>less</td>

<td>approximately</td><td> 75 %,</td><td>with</td><td>higher preference,</td><td>to the</td><td>less</td>

<td>approximately</td><td> 80 %,</td><td colspan="2">even more preferably,</td><td>to the</td><td>less</td>

<td>approximately</td><td> 85 %.</td><td>or with</td><td>the highest preference,</td><td>to the</td><td>less</td>

about 90%.

C. A Young's Modulus greater than about 2 Pascal (Pa), more preferably, greater than about 10 Pa, even more preferably, greater than about 20 Pa, even more preferably, greater than about 30 Pa, 40 Pa, 50 Pa, 75 Pa,

<img file="MX339063B_D0011.tif" />

OF INDUSTRIAL FROFIEDAD with the highest preference, greater than 100 Pa.

The term "surfactant component", as J description, means the totality of all anionic, nonionic, amphoteric, zwitterionic and cationic surfactants in one phase. When calculations are based on the surfactant component, water and electrolyte are excluded from calculations involving the surfactant component since surfactants are diluted and neutralized at the manufacturing stage.

The term "STnS" as used herein, means sodium trideceth sulfate, where n is defined as the average number of moles of ethoxylate per molecule. Trideceth is a 13-carbon branched ethoxylated hydrocarbon comprising, in one embodiment, an average of at least 1 methyl branch per molecule.

The term "SLS" as used herein, means sodium lauryl sulfate.

The term "foaming" as used herein, means the aerated foam that results from supplying energy to aqueous surfactant mixtures, especially dilute mixtures. Foaming was increased compared to the micellar compositions, e.g. eg, lamellar compositions, such that a phase change during dilution to micelles typically increases foaming.

As used in the present description, the term "inverted container" refers to a bottle that rests on the neck or mouth through which its contents are placed and administered, but which is also the end on which it rests ( eg, bottle base) for consumer storage or for display on the store shelf (this bottle is referred to in this description as “inverted container”).

&lt;·’

Typically, the lid of an inverted container is flat or how to store the container, it rests on the lid. The inverted containers in the US patent application pending. USA no. Serial No. 11/067443 filed February 25, 2005 by McCall, et al., entitled "Multi-phase Personal Care Compositions, Process for Making and Providing, and Article of Commerce." for its manufacture and supply, and article of

<img file="MX339063B_D0012.tif" />

Commerce).

The term "visually distinct," as used in the present description, refers to a region of the multiphase composition for personal care that has an average composition, so defined from another region that it has a different average composition, where the regions are visible to the naked eye. This would not prevent the different regions from being able to comprise two similar phases where one phase could comprise pigments, dyes, particles, and various optional ingredients and therefore a region of a different average composition. A phase generally occupies a space or several spaces with dimensions greater than that of the colloidal or subcolloidal components it comprises. A phase can be furthermore constituted or reconstituted, collected, or separated into a volume phase to observe its properties, for example, by centrifugation, filtration or the like.

An embodiment of the present invention relates to a cleansing composition comprising at least about 5% of a surfactant, at least 25% water, and a cyclodextrin complex comprising an oerfume, said perfume composition comprising at least one perfume selected from Iso-E Super, methyl ionone (Xandralia), a-lrona, ona, 10% Labienone Oxim (labienoxime) in DPG, Cashmeran, delta approximately raw material composition of gamma methyl or damascona, beta-ipnone, dihydro-beta-ionone, damascenone, trans-_Ty.aj

<img file="MX339063B_D0013.tif" />

INDUSTRIAL PROPERTY sconaen where the complex incorporation in the perfume premiums has a degree of complex formation of at least: 90 '% - before! ^{r 9} DF IA PROPERTY

<img file="MX339063B_D0014.tif" />

liquid body soap formulation, where 80% of the materials i have a degree of complex retention greater than 50% after incorporation into the liquid body soap composition, where the ratio of water to cyclodextrin complex it is between 15: 1 and 1: 1 within the body liquid soap composition.

Without theoretical limitations, cyclodextrin-fragrance complexes are believed to be released based on a dilution ratio (water: cyclodextrin-fragment complex). Surprisingly, it was found that the dilution ratio required for Ιε fragrance release is high enough to enable the formulation of a stable pure fragrance complex in an aqueous surfactant environment or, in addition to releasing in additional dilution in the shower (for create the surprising effect of changing the fragrance character during the shower) or release later in the day on the skin. The ability to tailor the release for the desired effect is highly dependent on the choice of perfume molecule and the strength of the cyc complex first beginning to use an odextrin formed. The strength of the complex formed requires that with a fragrance molecule that is, highly, bound by complex formation technology that achieves a high level of complex formation and second requires the selection of perfume molecules with a binding nourishing affinity within the cyclodextrin cavity. The binding affinity of fragrance molecules within the cyclodextrin cavity is governed by how well the perfume molecule fits (based on the size, shape, and chemical affinity of the molecule for the interior of the cyclodextrin cavity). It was learned that with careful selection of perfume molecules, this release can be adjusted to deliver the desired effects to the consumer through d |

MEXICAN INSTITUTE _ DE LA PROHEDAD multiple choice of highly binding fragrance molecules qiae^orWLfor by using a highly complex qtie complex formation technology. the materials.

theoretical imitations, there is another example where manipulation of the clclodextrlna is useful. This is in the case where you want to hide an odor even through the dilution stage, and still comply with the

No high dilution compound binder affinity, the ability to activate sensory receptors on the scalp. A highly usable combination is when menthol and cyclodextrin bind and Incorporate into antispark products.

For includes those cyclodextrin, for example, in the case of hair care products, which contain zinc pyrldinatlone, when menthol binds with do to the highly binding affinity of the complex in a shampoo, menthol is, relatively, odor free. Surprisingly, while the "tickling" effect of the application, no menthol can be felt on the scalp during / after the menthol odor exists. Accordingly, this complex surprisingly indicates efficacy with respect to tingling effect without any negative menthol odor.

This tingling sensation is unique in that it points to efficacy on the scalp surface, which is particularly useful for anti-dandruff products, without the negative menthol odor limiting the broad utility utility of menthol in care products. of hair.

Perfume raw materials

The perfume of the present invention comprises perfume raw materials (PRM) that are retained by the cyclodextrin complex. The PRMs of the present invention comprise a fractional supply value (FDV) of at least alternatively, at least about 0.80. Table 1 includes ir Iista ^ e

Acceptable DUSTIUAL of the present invention in conjunction with the fractional supply values ​​(FDF) of the PRM. In an alternate embodiment, the PRMs of the present invention include iso-E super, methyl ionone (Xandralia), a-irone, gamma methyl ionone, 10% Labienone Oxim (labienoxime) in DPG, cashmeran, delta-damascona, beta- ionone, dihydro-beta-ionone, damascenone, trans-, and alpha-damascone, all of which have a FDV of at least about 0.70.

The illustrative PRM and associated FDV are in Table 1, below. A person with ordinary ability will immediately know that this list is not exhaustive and that there may be additional PRMs that have a FDV of at least about 0.69.

Table 1

<td>Perfume base</td><td>FDV</td><td>Perfume base</td><td>FDV</td>

<td>Sclareol oxide</td><td> 0.88</td><td>Cashmeran</td><td> 0.73</td>

<td>Kefalis</td><td> 0.86</td><td>N-ethyl-p-menthane-3-carboxamide</td><td> 0.72</td>

<td>Maltil isobutyrate</td><td> 0.84</td><td>a-irona</td><td> 0.72</td>

<td>Floramat</td><td> 0.83</td><td>Isobutyl Angelato</td><td> 0.72</td>

<td>Cyclohexanecarboxylic acid, 2,2,6trimethyl-, ethyl ester, (1 R, 6S) -rel-</td><td> 0.82</td><td>Hexyl 2-methyl butanoate</td><td> 0.72</td>

<td>Patchouli alcohol</td><td> 0.81</td><td>Dihldro-alpha-ionone</td><td> 0.72</td>

<td>O-tert-Butylcyclohexyl acetate (verdox)</td><td> 0.81</td><td>Timberol</td><td> 0.72</td>

<td>Givescone</td><td> 0.81</td><td>Isobutyl caproate</td><td> 0.72</td>

<td>3,6-dimethyl-3-octanyl acetate</td><td> 0.81</td><td>Beta-Damascona (Econfiguration)</td><td> 0.72</td>

<img file="MX339063B_D0015.tif" />

<td>Acetic acid, hexylene glycol</td><td> 0.81</td><td>Beta-Damascona · 'J</td><td>P ^ &lt;</td>

<td>Thujopseno</td><td> 0.80</td><td>... INSTITUTE M Alpha-Vetivona r de ¡.ar_ANDr, iNi</td><td>torch USTRIAL</td>

<td>(+) - D-Mentil acetate</td><td> 0.80</td><td>Hexyl isobutarate '</td><td> 0.72</td>

<td>Isomenthyl acetate</td><td> 0.80</td><td>Dimethyl octanyl acetate</td><td> 0.72</td>

<td>Mentyl acetate;</td><td> 0.80</td><td>Gamma methyl ionone</td><td> 0.72</td>

<td>dl-MENTIL ACETATO</td><td> 0.80</td><td>Linalyl butyrate</td><td> 0.72</td>

<td>Mentyl Acetate</td><td> 0.80</td><td>Herboxan</td><td> 0.72</td>

<td>Tetrahydrolinalyl acetate</td><td> 0.80</td><td>Cetonal</td><td> 0.72</td>

<td>Pliers</td><td> 0.80</td><td>Grisalva</td><td> 0.72</td>

<td>Dihydroterpinyl acetate</td><td> 0.80</td><td>1 - (2,6,6-tr-methyl-2-cyclohexene-1-yl) -2-buten-1-one</td><td> 0.71</td>

<td>Rosamusk</td><td> 0.79</td><td>Alpha-damascone</td><td> 0.71</td>

<td>Amber acetate</td><td> 0.79</td><td>Nopilo acetate</td><td> 0.71</td>

<td>Hydroxytoluene butylate</td><td> 0.79</td><td>p-tert-Amill cyclohexanol</td><td> 0.71</td>

<td>Koavone</td><td> 0.79</td><td>Alpha-I3ergamotene</td><td> 0.71</td>

<td>3-Thujopsanone</td><td> 0.78</td><td>Isopentyl butyrate</td><td> 0.71</td>

<td>Alpha-Himalelene</td><td> 0.78</td><td>Delta-Damascona</td><td> 0.71</td>

<td>Beta-himalelene</td><td> 0.78</td><td>Germacrene D</td><td> 0.71</td>

<td>Ethyl beta safranate</td><td> 0.78</td><td>1,1,2,3,3-pentamethylindane</td><td> 0.71</td>

<td>Ethyl gamma safranate</td><td> 0.78</td><td>Rossitol</td><td> 0.71</td>

<td>Ethyl Alpha Safranate</td><td> 0.78</td><td>Myrcenyl acetate</td><td> 0.71</td>

<td>Alpha-Terpinyl Acetate</td><td> 0.78</td><td>Datilat</td><td> 0.71</td>

<td>Gamma-himacalene</td><td> 0.78</td><td>Undecanolide</td><td> 0.71</td>

<td>Beta-himalelene oxide</td><td> 0.78</td><td>Pentanoic Acid, 2-Methyl-, Ethyl Ester (Manzanate)</td><td> 0.71</td>

<td>Vertenex</td><td> 0.77</td><td>Eucalyptol</td><td> 0.70</td>

<td>4-ter Butylcyclohexylacetate</td><td> 0.77</td><td>Beta-ionone</td><td> 0.70</td>

<td>Alpha-Terpinyl Propionate</td><td> 0.77</td><td>Beta-ionone epoxide</td><td> 0.70</td>

<td>Trichloromethyl phenyl carbinyl acetate</td><td> 0.77</td><td>4-tert-amylcyclohexanone</td><td> 0.70</td>

<td>Alpha-COPAENE</td><td> 0.77</td><td>Tetrahydrolinalol (tetrahydro linalol)</td><td> 0.70</td>

<td>G-Terpineol Acetate</td><td> 0.77</td><td>Butanol amber (amber core)</td><td> 0.70</td>

<img file="MX339063B_D0016.tif" />

<td>Vanoris</td><td> 0.77</td><td>Veticol acetate</td><td> 0.70</td>

<td>Sclareolate</td><td> 0.77</td><td>Hexyl Tiglate 11V1 J</td><td>^ olkfC</td>

<td>Iso-E super</td><td> 0.77</td><td>_, OF THE PRO Gamma- damascone ^{, NDl}</td><td> ^70^</td>

<td>.Beta-Georgywood</td><td> 0.77</td><td>Nootkatone</td><td>0.7Q</td>

<td>Cariolan-1-ol</td><td> 0.77</td><td>Alpha-lonona</td><td> 0.70</td>

<td>Boisiris</td><td> 0.77</td><td>T rans-2-tert-butylcyclohexanol</td><td> 0.70</td>

<td>2-isopropyl, 2,3-trimethylbutyramide</td><td> 0.76</td><td>Verdol</td><td> 0.70</td>

<td>Selina-3,7 (11) -diene</td><td> 0.76</td><td>Wolfwood</td><td> 0.70</td>

<td>Zonareno</td><td> 0.76</td><td>Pomarose</td><td> 0.70</td>

<td>Delta Amorphene</td><td> 0.76</td><td>6,8-dimethyl-2-nonanol</td><td> 0.70</td>

<td>Delta-Cadinene</td><td> 0.76</td><td>Jasmal</td><td> 0.70</td>

<td>Beta-Copane</td><td> 0.76</td><td>Methyl ionone (Xandralia)</td><td> 0.70</td>

<td>Bigarade oxide</td><td> 0.76</td><td>Cis-3-Hexenyl 2-methylbutyrate</td><td> 0.70</td>

<td>Dodecane tobacco</td><td> 0.76</td><td>Tetrahydromyrcenol</td><td> 0.70</td>

<td>Dihydrocarveol acetate</td><td> 0.76</td><td>Maceal</td><td> 0.70</td>

<td>Alpha-Cadinene</td><td> 0.76</td><td>Diethyl malonate</td><td> 0.70</td>

<td>Alpha-Murolene</td><td> 0.76</td><td>Citronellyl acetate</td><td> 0.70</td>

<td>Alpha-Amorphene</td><td> 0.76</td><td>Dimethylbenzylcarbinyl acetate</td><td> 0.70</td>

<td>Valerianol</td><td> 0.75</td><td>Delta- decalactone</td><td> 0.70</td>

<td>Gamma-Eudesmol</td><td> 0.75</td><td>Methyl-beta-ionone</td><td> 0.70</td>

<td>10-epi-gamma-Eudesmol</td><td> 0.75</td><td>BORONAL</td><td> 0.70</td>

<td>Hexyl Neopentanoate</td><td> 0.75</td><td>10% Labienone Oxim (labienoxime) in DFG</td><td> 0.70</td>

<td>Alpha Terpinyl Acetate</td><td> 0.75</td><td>Damascenone-</td><td> 0.70</td>

<td>Octalinol</td><td> 0.75</td><td>2-Buten-1 -one, _1 - (2,6,6-trimethyl1,3-cyclohexadien-1-yl) -</td><td> 0.70</td>

<td>Alpha-Cadinol</td><td> 0.75</td><td>Caryophylene Acetate Alcohol</td><td> 0.70</td>

<td>Tau-murolol</td><td> 0.75</td><td>Isodamascone</td><td> 0.70</td>

<td>Tau-cadinol</td><td> 0.75</td><td>Ethyl 3,7-dimethyl-2,6-octadienoate</td><td> 0.69</td>

<td>Tetrahydroionol</td><td> 0.75</td><td>Gelsone</td><td> 0.69</td>

<td>7-eip-alfa-eudesmol</td><td> 0.75</td><td>Ciclemone A</td><td> 0.69</td>

... &lt;kw

<img file="MX339063B_D0017.tif" />

<td>Alpha-eudesmol</td><td> 0.75</td><td>Delta-Undecalactone Τ ΑΛ</td><td></td>

<td>Delta-elemen</td><td> 0.75</td><td>-A Jl * Jl Spentyl Propanoate</td><td>ΟΡΙΡΠαΓ »</td>

<td>Clarycet</td><td> 0.75</td><td>- Verdural B Extra</td><td>) USTR! AL 0.69</td>

<td>Isopentirate</td><td> 0.75</td><td>5-acetyl-1,1,2,3,3,6- ' hexametlllndan</td><td> 0.69</td>

<td>Valencene</td><td> 0.75</td><td>Diethyl phthalate</td><td> 0.69</td>

<td>Linalyl isobutyrate</td><td> 0.74</td><td>Veltonal</td><td> 0.69</td>

<td>7-ep¡-alfa-sel¡neno</td><td> 0.74</td><td>Alpha-methylionone</td><td> 0.69</td>

<td>Alpha-selinen</td><td> 0.74</td><td>Chin 1,2-glycerol ketal (racemic)</td><td> 0.69</td>

<td>Gamma-muroleno</td><td> 0.74</td><td>Dihydro terpineol</td><td> 0.69</td>

<td>Gamma Cadinene</td><td> 0.74</td><td>Patchone</td><td> 0.69</td>

<td>Beta-caryophyllene</td><td> 0.74</td><td>Ethyl octanate</td><td> 0.69</td>

<td>Ozofleur</td><td> 0.74</td><td>Limethol</td><td> 0.69</td>

<td>Elemol</td><td> 0.74</td><td>Oxano</td><td> 0.69</td>

<td>Linalyl acetate</td><td> 0.74</td><td>Alpha-agarofuran</td><td> 0.69</td>

<td>Herbavert</td><td> 0.74</td><td>n-pentllo butyrate</td><td> 0.69</td>

<td>7-Acetyl-1,1,3,4,4,6-hexamethyltetralin</td><td> 0.74</td><td>Para-Methane</td><td> 0.69</td>

<td>Isoamyl isobutyrate</td><td> 0.74</td><td>Felandreno</td><td> 0.69</td>

<td>Linalyl propionate</td><td> 0.74</td><td>Cyclohexane, 1-methyl-4- (1-methyl-ethyl) -, cis-</td><td> 0.69</td>

<td>Methyl chamomile</td><td> 0.74</td><td>3-Hexenyl isovalerate</td><td> 0.69</td>

<td>Carvilo acetate</td><td> 0.74</td><td>Menthol</td><td> 0.69</td>

<td>Alpha-Humulene</td><td> 0.73</td><td>Clclohexanol, 5-methyl-2- (1methyl) -, (1 .al</td><td> 0.69</td>

<td>Germacrene B</td><td> 0.73</td><td>Neo-menthol</td><td> 0.69</td>

<td>Alpha, 4-dimethill benzenepropanal</td><td> 0.73</td><td>(+) - D-menthol</td><td> 0.69</td>

<td>Alpha- some millionaire</td><td> 0.73</td><td>(-)-menthol</td><td> 0.69</td>

<td>Angelato by isoamilo</td><td> 0.73</td><td>d-neomenthol</td><td> 0.69</td>

<td>Frutlnat</td><td> 0.73</td><td>Isononyl acetate</td><td> 0.69</td>

<td>Oxloctallno formlate</td><td> 0.73</td><td>cis-pinean</td><td> 0.69</td>

<td>Lavandulil Acetate</td><td> 0.73</td><td>Ethyl heptanate (Ethyl oenantate)</td><td> 0.69</td>

<img file="MX339063B_D0018.tif" />

· * «* · ** &lt;· -. .w ^^ * 4444,: .. ^

<td>Beta-Selinene</td><td> 0.73</td><td>Tabanone J</td><td></td><td></td>

<td>Isopropyl 2-methylbutyrate</td><td> 0.73</td><td>INSTITUTE ME 3,5,5-trimethyl-1-hexanol ^OF "Ή</td><td>STEM</td><td></td>

<td>Dihldro- beta-ionone</td><td> 0.73</td><td>P-Cresyl isobutyrate</td><td> 0.69</td><td></td>

<td>Floralate</td><td> 0.73</td><td></td><td></td><td></td>

It is contemplated that PRMs having a FDV of less than about 0.69 (L-PRM) can be used in combination with PRMs having a FDV of at least about 0.69 (H-PRM). Such consideration allows the supply of L-PRM before a provoked dilution step, since these materials are less bound to cyclodextrin. Thus, the supply of materials can be controlled within a perfume and a product that depends on the desired characteristics for the supply of perfume. When staged delivery of PRM is desired, the ratio of H-PRM to L-PRM is between about 1: 2 to about 2: 1, alternatively between about 1: 4 and 4: 1.

The ARDON test has been developed as a mechanism to determine if general perfume release uses complex cyclodextrins within a body of liquid body soap. In this way, the presence of PRM with sufficiently high FDV values ​​can be determined without the need to test each individual PRM to determine the presence or without knowing the final formulation of the final product.

Without theoretical limitations, it is believed that the dilution of the product when it contains cyclodextrin and H-PRM results in a significantly higher ARDON value than products either without cyclodextrin or H-PRM within its structure. This mechanism allows product testing to determine delivery mechanisms without the need to know the chemical composition of the product. The present invention uses compositions having an ARDON value of at least about 130%, alternatively, at least about 140%, alternatively, at least about 150%.

Surfactant phase

One of the phases of the personal care composition of the present invention is a surfactant phase. The surfactant phase comprises a structured domain comprising a surfactant and, optionally, a cosurfactant. The structured domain is preferably an opaque structured domain that is preferably a lamellar phase. The lamellar phase can provide shear resistance, adequate performance to suspend particles and droplets, and at the same time provide long-term stability, since it is thermodynamically stable. The sheet phase tends to have a viscosity that minimizes the need to use viscosity modifiers.

In one embodiment, the personal care compositions of the present invention comprise from about 3% to about 20% of

STnS, alternatively, from about 5% to about 15% STnS, alternatively, from about 7% to about 13% STnS, alternatively, from about 5% to about 13% STnS, alternatively, from about 1% to about 13 % of STnS.

STnS having less than 3 moles of ethoxylation were found to offer surprising structural improvements. Figure 1 illustrates these improvements by comparing a composition comprising, ST1S, ST2S, and ST3S. By increasing dilution levels, ST3S initiates the transition from a lamellar structure to a micellar structure that begins at approximately 19% of the surfactant level. As such, dilution beyond this level results in a loss of structure. This loss of structure has, until now, the need for them to be present

<img file="MX339063B_D0019.tif" />

higher surfactant concentrations within a package. ST2S compositions can remain well structured up to a pu ^ q ^^^ p ^ n '.

FROM THE INDUSTRIAL REDUCTION of the surfactant within this example, allowing the transition to a more micellar structure at much higher dilution levels. ST1S compositions can remain lamellar at even lower surfactant concentrations.

Although sodium trideceth sulfate has been described and marketed, the use and benefits of sodium trideceth sulfate having lower ethoxylation values ​​is unknown, additional reasoning supported by the general popularity of ST3S within commercially available products, and the lack of commercial availability of lower ethoxylation products. It is this unknown and surprising result that allows for various benefits of the personal care compositions of the present invention, including improved stability, softness, compatibility, and foaming.

Without claiming to be bound by theory, the rationale for better STNS function, where n is below 3, can be illustrated through the use of dynamic dissipative particle simulations (DPD). As for STnS, the surfactant aggregates form curved surfaces based on the shape of the surfactant and the interactions between the molecules, resulting in phase surfactant architectures; and to the degree of phase structure as measured by rheological parameters, such as zero shear viscosity. To measure the amount of curvature of the surfactant, molecular simulations were performed using DPD by breaking surfactant atoms into globules, where one globule typically represents 3-4 heavy atoms. Simulations were performed in a cube cell with an edge length of approximately 25nm. The compositions of the simulation boxes varied in the average amount of ethoxylation (n = 0 to 3) of STnS. The assembly of the

<img file="MX339063B_D0020.tif" />

Surfactants in aggregates with onset from random positions were observed during the course of the simulations. The DPD curvature was calculated J ^ rlo-íEní¹

MEXICAN INSTITUTE OF PROPERTY Average of multiple independent simulations for the surface-water surface group of the surfactant of all resulting objects in a simulation framework, which includes all bilayers and micelles, and is a relative measure of the average surface deviation colligative of the main surfactant group from the plane. Zero DPD curvature are flat layers with edge defects, which do not form multilamellar vesicles and are therefore not expected to show structured rheology, e.g. eg, high zero shear viscosity. At DPD curvature of approximately 0.07 and above, elongated micellar structures were observed to form. At intermediate DPD curvature, the curved bilayers can form multilamellar vesicles, leading to high zero shear viscosity and stable compositions.

STnS is often combined with SLS to form a surfactant system. In one embodiment, the personal care compositions of the present invention comprise less than about 5% SLS, alternatively less than about 4% SLS, alternatively less than about 3% SLS, alternatively less than about 2% of SLS, alternatively less than about 1% SLS, alternatively between about 0.1% SLS and about 2% SLS, alternatively about 0% SLS. Without intending to be bound by theory, the presence of SLS is believed to increase the hardness of the personal care composition, which at least in part negates the softness and / or efficacy benefits of beneficial agents within the composition. for personal care.

Cosurfactant

<img file="MX339063B_D0021.tif" />

. . . .... . MIXICAN INSTITUTE.

The personal care compositions of fa^{D [}pq $ ^ | $ ”inMqjeSsk additionally comprise a cosurfactant. The cosurfactants in the present invention comprise from about 0.1% to 20%, alternatively from about 2% to about 10% of the personal care composition. The cosurfactants of the present invention comprise amphoteric surfactants, zwltterionic surfactants, and mixtures thereof. In one embodiment, the personal care composition comprises at least one amphoteric surfactant. Amphoteric surfactants suitable for use in the present invention include those generally described as secondary and tertiary aliphatic amine derivatives in which the allphatic radical can be straight-chain or branched-chain and in which one of the aliphatic substituents contains from about 8 to about 18 carbon atoms and one contains an anionic group for solubilization in water, e.g. ex. carboxyl, sulfonate, sulfate, phosphate, or phosphonate. Examples of compounds included in this definition are sodium 3-dodecylaminopropionate, sodium 3-dodecylaminopropanesulfonate, sodium lauryl sarcosinate, N-alkylIltaurines, such as that prepared by reaction of dodecylamine with sodium sesionate, according to the teachings of the US patent USA no. 2,658,072, long-chain N-alkyl of aspartic acids, such as those produced according to the teachings of US Pat. USA no. 2,438,091, and the products described in US Pat. USA no. 2,528,378. In one aspect, the multi-phase personal care composition may comprise an amphoteric surfactant that is selected from the group consisting of sodium lauroamphoacetate, sodium lafoamphoacetate, disodium lauroamphoacetate, disodium cocodianfoacetate, and mixtures thereof. In addition, amphoacetates and dianfoacetates can also be used.

Suitable zwitterionic surfactants include those that are

<img file="MX339063B_D0022.tif" />

widely described as derivatives of aliphatic compounds ^

MEXICAN INSTITUTE phosphome and sulfonium, in which the aliphatic radicals can branch, and where one of the aliphatic substituents comprises from about 8 to about 18 carbon atoms, and another one comprises an anionic group, for example, carboxy, sultanate, sulfate, phosphate, or phosphonate. Suitable zwitterionic surfactants for use in the multiphase personal care composition include betaines, including cocoamidopropyl betaine.

Associative polymer

In one embodiment, the associative polymer is a crosslinked alkali swellable associative polymer, comprising acidic monomers and associative monomers with hydrophobic end groups, whereby the polymer comprises a percent hydrophobic modification and a hydrophobic side chain comprising alkaline functional groups that have a length. Without intending to be limited by theory, it is believed that acidic monomers contribute to the ability of the polymer to swell in water upon neutralization of the acid groups; and associative monomers anchor the polymer in hydrophobic domains of the structured surfactant, e.g. Eg, lamellae, to confer structure to the surfactant compositions and prevent the polymer from collapsing and losing efficacy in the presence of the electrolyte. The crosslinked associative polymer comprises a percent hydrophobic modification, which is the mole percent of monomers expressed as a percent of the total number of all monomers in the polymer backbone, which includes both acidic and other non-acidic monomers . The percent hydrophobic modification of the polymer, hereinafter% HM, can be determined by the ratio of monomers added during synthesis, or by analytical techniques such as proton nuclear magnetic resonance (NMR). The length of the alkyl side chain can be similarly determined. Monomers

or less alkyl hydrocarbons (eg ethyl, methyl) na^tseg ^^ i ^ ®i

INDUSTRIAL

<img file="MX339063B_D0023.tif" />

For the purposes of the present invention, all side chains having more than 2 carbons are associative. Associative alkyl side chains comprise, for example, butyl, propyl, stearyl, esteareth, cetyl, lauryl, lauret, octyl, behenyl, beheneth, esteareth, or other linear or branched, saturated or unsaturated alkyl or alketh hydrocarbon side chains.

Crosslinked associative polymers having the preferred% HM and preferred carbon numbers of the hydrophobic end groups of the alkyl side chains were found to provide a significant improvement in structure to the structured surfactant compositions of the present invention, especially the compositions inventives involving reduced levels of surfactant; and supply such a structure at surprisingly low levels of the structuring polymer. Associative polymer concentrations of up to 5% or even 10% are taught in the art to obtain a sufficient amount of the structure, for example, the Illustrative compositions of US Pat. USA 7,119,059 (Llbrlzzl, et al.) And 6,897,253 (Schmucker-Castner, et al.). The Inventors found that when the% HM of the associative polymer and the number of carbons of the alkyl side chain is optimized, the aqueous phase structure of the structured surfactant is increased by the use of only less than 3% by weight of the associative polymer as a percent of the aqueous phase of the structured surfactant, preferably less than 2%, more preferably less than 1%, and even only about 0.2% of the phase, as demonstrated by the inventive examples hereinafter.

The acidic monomer can comprise any acidic functional group, for example, sulfate, sulfonate, carboxylate, phosphonate, or phosphate or mixtures of acid groups. In one embodiment, the acidic monomer co i ivi ri alternatively, the acidic monomer is an acrylate, which ac® *⁷ INDUSTRIAL

methacrylic acid. The acidic monomer comprises a polymerizable structure, for example, vinyl functionality. Mixtures of the acidic monomers, for example, mixtures of the acrylic acid and methacrylic acid monomers, are useful.

The associative monomer comprises a hydrophobic end group and a polymerizable component, e.g. eg vinyl, which are bonded. The hydrophobic end group can be attached to the polymerizable component, hence to the polymer chain, by different means but is preferably attached by an ether or ester or amide functionality, such as an alkyl acrylate monomer or a vinyl alkanoate. The hydrophobic end group can be further separated from the chain, for example, by an alkoxy ligand such as an alkyl ether. In one embodiment, the associative monomer is an alkyl ester, alternatively an alkyl (meth) acrylate, where (meth) acrylate is understood to mean either methyl acrylate or acrylate or mixtures of the two.

In one embodiment, the hydrophobic end group of the associative polymer is incompatible with the composition of the aqueous phase and is associated with the foaming surfactant hydrophobic components of the present invention. Without intending to be bound by theory, it is believed that the longer alkyl chains of the end groups of the structuring hydrophobic polymer increase the incompatibility with the aqueous phase to improve structure, while the somewhat shorter alkyl chains having numbers of carbon very similar to hydrophobic foaming surfactant (eg, 12 to 14 carbons) or multiples of it (by bilayers, eg. eg) they are also effective, making a variety of preferred materials that balance these opposing requirements ideally, limited by the solubility of the total molecule itself. Polymers having short alkyl side chains, e.g. eg, less than 6 carbons, are ineffective for

INSTITUTO MEXICANO inventors discovered an ideal range of numbers of carbóüf ^ ftgft gWgeiáigsj »* hydrophobic end which combined with an optimal percent of hydrophobic monomers expressed as percent of the polymer backbone provides the increased structure for the composition of the structured surfactant, foaming, at low levels of the structuring polymer.

Preferred associative polymers comprise approximately C16 (cetyl) alkyl hydrophobic side chains with approximately 0.7% hydrophobic modification, but the percent hydrophobic modification may be up to the limit of aqueous solubility in the surfactant compositions, e.g. eg, up to 2% or 5% or 10%. An illustrative preferred associative polymer is Aqupec SER-300 manufactured by Sumitomo Seika of Japan, which is the Acrylates / C10-30 alkyl acrylate crosslinked polymer and comprises stearyl side chains with less than about 1% HM. Other preferred associative polymers include stearyl, octyl, decyl, and lauryl side chains. Preferred associative polymers are Aqupec SER-150 (Acrylates / C10-30 alkyl acrylate crosslinked polymer) comprising approximately C18 (stearyl) side chains and approximately 0.4% HM, and Aqupec HV-701EDR comprising about C8 (octyl) and about 3.5% HM. Another preferred polymer is Stabylen 30 manufactured by Sigma 3V SpA, which has branched isodecanoate hydrophobic associative side chains. Importantly, the inventors discovered that not all crosslinked associative polymers are effective, many are detrimental to the structure. Associative polymers having hydrophobic side chains with less than 7 carbons and having a% HM greater than about 25% or about 50% are not preferred. For example, Carbopol

Aqua SF-1 (crosslinked acrylate copolymer) having alkyl side chains with an average "mi" of 4.5 carbons and more than 50% HM is deleterious in the examples below.

P &lt;a

MEXICAN INSTITUTE OF PROPERTY

INDUSTRIAL

<img file="MX339063B_D0024.tif" />

Deposition polymers

The personal care compositions of the present invention may further comprise an organic cationic deposition polymer in one or more phases as an auxiliary deposition for the beneficial agents described herein. Suitable cationic deposition polymers for use in the compositions of the present invention contain nitrogen-containing cationic entities, such as quaternary ammonium entities. Non-limiting examples of cationic deposition polymers for use in the personal cleansing composition include polysaccharide polymers, such as cationic cellulose derivatives. Preferred cationic cellulose polymers are hydroxyethyl cellulose salts reacted with substituted trimethylammonium epoxide, known in the industry (CTFA) as Polyquaternium 10 and available from Amerchol Corp. (Edison, NJ, USA. UU) in its series of JR and LR polymers and KG Polymer, the most preferred being KG-30M. Other suitable cationic deposition polymers include cationic guar gum derivatives, such as guar hydroxypropyltrimonium chloride, the specific examples of which include the Jaguar series (preferably Jaguar C-17) commercially available from Rhodia Inc., the commercially available N-Hance polymer series. Available from Aqualon.

In one embodiment, the deposition polymers of the present invention have a cationic charge density of from about 0.8 meq / g to about 2.0 meq / g, alternatively from about 1.0 meq / g to about 1.5 meq / g.

Water

<img file="MX339063B_D0025.tif" />

The surfactant phase of the present invention or

In one embodiment, the surfactant phase of the personal care composition comprises from about 10% to about 90%, alternatively, from about 40% to about 85%, alternatively, from about 60% to about 80% by weight of water.

Charity phase

The personal care composition of the present invention comprises a beneficial phase. The beneficial phase in the present invention is preferably hydrophobic or practically anhydrous and can be practically free of water. The beneficial phase can be free or practically free of surfactant.

The beneficial phase typically comprises beneficial agents. Beneficial agents include water insoluble or hydrophobic beneficial agents. The beneficial phase may comprise from about 0.1% to about 50%, preferably from about 1% to about 30%, from about 5% to about more preferably, 30% by weight of the personal care composition, of an agent beneficial.

The hydrophobic skin benefit agent for use in the benefit phase of the composition has a Vaughan solubility parameter (VSP) of from about 5 to about 15, preferably from about 5 to less than 10. These solubility parameters are well known in formulation techniques and defined by Vaughan in Cosmetics and Toiletries, Vol. 103, p. 47-69,

Oct. 1988.

Non-limiting examples of glycerides suitable for use as hydrophobic, skin beneficial, nuunw agents in the present invention included J Jic ^

MEXICAN SOYBEAN INSTITUTE, soy bean derivatized oils such as aeéiW $$ g $ ja safflower oil, cottonseed oil, corn oil, castile walnut oil, peanut oil, olive oil, oil of cod liver, almond oil, avocado oil, palm oil and sesame oil, vegetable oils, sunflower seed oil, derived from vegetable oils; coconut oil and coconut oil derivatives, cottonseed oil and cottonseed derivatives, jojoba oil, cocoa butter, and combinations thereof.

Non-exhaustive examples of acetoglyceride esters suitable for use as hydrophobic skin benefit agents herein include acetylated monoglycerides.

<img file="MX339063B_D0026.tif" />

Non-limiting examples of suitable alkyl esters for use as hydrophobic skin benefit agents in the present invention include isopropyl esters of fatty acids and long chain esters of long chain fatty acids (ie C10-C24), p . For example, cetyl ricinoleate, non-limiting examples include isopropyl palmitate, isopropyl myristate, cetyl riconoleate, and stearyl riconoleate. Other examples are: hexyl laurate, isohexyl laureate, myristyl myristate, isohexyl palmitate, deciloleate, isodecyl oleate, hexadecyl stearate, isopropyl isostearate, diisopropyl adipate, diisohexyl adipate, dihexildecyl adipate lauryl lactate, myristyl lactate, cetyl lactate, and combinations thereof.

Non-exhaustive examples of alkenyl esters suitable for use as hydrophobic skin benefit agents herein include oleyl myristate, oleyl stearate, oleyl oleate, and combinations thereof.

Non-limiting Examples of Polyglycerol Esters of Fatty Acids

<img file="MX339063B_D0027.tif" />

suitable for use as hydrophobic beneficial agents for the spieheiíxlajRi

PE IA l'Ri lPIEPAD 'NPUSruiAt invention include decaglyceryl distearate, decaglyceryl diisoestearate, decaglyceryl monomyriate, decaglyceryl monooleate, glycerin monooleate glycerol monooleate and combinations of these.

Non-exhaustive examples of lanolin and lanolin derivatives suitable for use as hydrophobic skin benefit agents in the present invention include lanolin, lanolin oil, lanolin wax, lanolin alcohols, lanolin fatty acids, isopropyl lanolate, acetylated lanolin, acetylated lanolin alcohols, lanolin alcohol linoleate, lanolin alcohol riconoleate, and combinations thereof.

Non-exhaustive examples of silicone oils suitable for use as hydrophobic skin benefit agents of the present invention include dimethicone copolyol, dimethylpolysiloxane, diethylpolysiloxane, C1-C30 alkyl mixed polysiloxanes, phenyl dimethicone, dimethiconol, and combinations thereof. Non-volatile silicones selected from dimethicone, dimethiconol, combined C1-C30 alkyl polyxyloxanes, and combinations thereof are preferred. Non-exhaustive examples of silicone oils useful in the present invention are described in US Pat. USA no. 5,011,681 (Ciotti et al.).

Still other suitable hydrophobic skin benefit agents include milk triglycerides (eg, hydroxylated milk glyceride) and fatty acid polyesters of fatty acids.

Still other suitable hydrophobic skin benefit agents include wax esters, non-exhaustive examples of which include beeswax and beeswax derivatives, spermaceti, myristyl myristate, stearyl stearate, and combinations thereof. In addition, candelilla wax waxes are useful; sterols such as cholesterol, esters of '^orSqR3 ^^ aá cholesterol; and phospholipids such as lecithin and derivatives, sphingolipids, ceramides, glycosphingo lipids, and combinations thereof. Furthermore, suitable beneficial agents include glycerin monooleate.

MEXICAN INSTITUTE

<img file="MX339063B_D0028.tif" />

Solid and active skin particles

The compositions may optionally comprise the following skin beneficial ingredients to improve the delivery of these beneficial materials to the skin.

A) Flaking assets

Flaking actives enhance the skin appearance benefits of the present invention. For example, flaking assets tend to improve skin texture (eg, smoothness). A flaking system suitable for use in the present invention contains sulfhydryl compounds and zwitterionic surfactants and is described in US Pat. USA no. 5,681,852, to Bissett. Preferred concentrations of flaking actives range from about 0.1% to 10%, more preferably from about 0.2% to 5%, even more preferably from about 0.5% to 4%, by weight of the personal cleansing composition.

Another flaking system that is suitable for use in the present disclosure contains salicylic acid and zwitterionic surfactants and is described in US Pat. USA no. 5,652,228 to Bissett. Zwitterionic surfactants, such as those described in these applications, are furthermore useful as descaling agents herein, where, in particular, cetyl betaine is preferred. _ _ _ '' MFXIONO INSTITUTE OF PROPERTY

INDUSTRIAL

B) Antiarruaas assets / Antiatrophy assets

Anti-wrinkle actives or anti-atrophy actives include sulfur-containing D and L amino acids and their derivatives and salts, particularly N-acetyl derivatives. A preferred example which is N-acetyl-L-cysteine; thiols, e.g. eg, ethanothiol; hydroxy acids (e.g. eg, alpha hydroxy acids such as lactic acid and glycolic acid or beta-hydroxy acids such as salicylic acid and derivatives of salicylic acid such as the octanoyl derivative), phytic acid, lipoic acid; lysophosphatidic acid, and skin peeling agents (eg, phenol and the like).

Hydroxy acids as active skin agents in the present invention include salicylic acid and derivatives of salicylic acid. Preferred concentrations of anti-wrinkle / anti-atrophy actives range from about 0.01% to 50%, more preferably from about 0.1% to 10%, even more preferably from about 0.5% to 2%, by weight of the cleaning composition personal.

Other non-limiting examples of anti-wrinkle actives suitable for use in the present disclosure are described in US Pat. USA no. 6,217,888, issued to Oblong et al.

C) Antioxidants / Radical scavengers

Some non-limiting examples of antioxidants or radical scavengers that can be used in the present invention include ascorbic acid and its salts, fatty acid and ascorbyl esters, ascorbic acid (eg, ascorbyl and magnesium phosphate, ascorbyl and sodium phosphate, sorbate ascorbyl), tocopherol, tocopherol acetate, other tocopherol esters, butylated hydroxybenzoic acids and their salts, 6-hydroxy-2,5,7,8-tetrameticroman-2-carboxylic acid (commercially available as Trolox®), gallic acid and its esters of alqt ^ op ^ p ^ ia ^ ent propyl gallate, uric acid and their salts and alkyl esters, sorbic acid &lt;yy ^ ljg, ^^ g ^ lipoic, amine (for example, Ν, Ν-diethylhydroxylamine, aminoguanidine), sulfhydric compounds (for example glutathione), dihydroxyfumaric acid and its salts, lichen pidolate, arginine pilolate, nordihiguayaretic acid, bioflavonoid, curcumin, lysine, mmetholin, proline, superoxide dismutase, silymarin, tea extract, grape peel / seed extract, melanin and rosemary extract. Preferred concentrations range from about 0.1% to 10%, more preferably from about 1% to 5%, by weight of the personal cleansing composition.

D) Chelating agents

The term "chelating agent" or "chelating agent" refers to skin active agents capable of removing a metal ion from a system by the formation of a complex so that the metal ion cannot easily participate in or catalyze chemical reactions .

Chelating agents as skin active agents for use in the present invention are preferably included in concentrations ranging from about 0.1% to 10%, more preferably from about 1% to 5%, by weight of the composition of personal cleanliness. Non-limiting examples of suitable chelating agents are described in US Pat. USA no. 5,487,884, issued January 30, 1996 to Bissett et al .; international publication no. 91/16035, Bush et al., Published October 31, 1995; and international publication no. 91/16034, Bush et al., Published October 31, 1995.

A preferred chelating agent for use in the compositions of the present invention include disodium EDTA, and derivatives thereof.

<img file="MX339063B_D0029.tif" />

E) Anti-cellulite agents

Non-exhaustive examples of anti-cellulite agents incliXewOTt ^ u ^ st ^ '^^:

INSTITUTO MEXICANO DE LA ROPIEHaD xanthine such as caffeine, theophylline, theobromine, aminophylline, and combinations thereof. Anti-cellulite agents preferably include erf concentracioné τρο ranging from about 0.1% to 10%, more preferably from about 1% to 5%, by weight of the personal cleansing composition.

F) Tanning assets

Non-exhaustive examples of these tanning agents include the hydrochloride ketone, also known as DHA or 1,3-dihydroxy-2-propanone. Tanning assets are preferably included in concentrations ranging from about 0.1% to 10%, more preferably from about 1% to 5%, by weight of the personal cleansing composition.

G) Skin clarifying agents

Non-exhaustive examples of clarifying agents suitable for use in the present invention include kojic acid, arbutlna, ascorbic acid and derivatives thereof (eg, ascorbyl magnesium phosphate or sodium ascorblum phosphate) and extracts (eg, blackberry extract , placenta extract). Non-limiting examples of skin lightening agents suitable for use in the present invention further include those described in

WO 95/34280, WO 95/07432, and WO 95/23780. Skin clarifying agents are preferably included at concentrations ranging from about 0.1% to about 10%, more preferably from about 1% to about 5%, by weight by weight of the personal cleansing composition.

H) Skin soothing and skin healing assets

Non-exhaustive examples of soothing and cf active ingredients suitable for use in the present invention include acid derivatives.

<img file="MX339063B_D0030.tif" />

FROM INDUSTRIAL Pantothenic Ri'Cf'ÍEDAD (eg, panthenol, dexpanthenol, ethyl panthenol), aloe, allantoin, bisabolol, and dipotassium glycyrrhizinate. The skin soothing and skin healing actives are preferably included in concentrations ranging from about 0.1% to 10%, more preferably from about 1% to 5%, by weight of the personal cleansing composition.

I) Antimicrobial assets

Limiting examples of antimicrobial actives for use in the present disclosure include β-lactam drugs, quinolone drugs, ciprofloxacin, norfloxacin, tetracycline, erythromycin, amikacin, 2,4,4'-tr-chloro-2^,-hydroxydiphenyl ether, 3,4,4'-trichlorobanilide, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, doxycycline, capreomycin, chlorhexidine, chlortetracycline, oxytetracycline, metadamycin, ethanamine, metronidaine, metronidaine , methenamine, minocycline, neomycin, netilmicin, paromomycin, streptomycin, tobramycin, miconazole, tetracycline hydrochloride, erythromycin, erythromycin zinc, erythromycin stolate, erythromycin sterorate, amikacin sulfate, doxycycline hydrochloride, capreomycin sulfate, chlorhexidine gluconate, chlorhexidine hydrochloride, chlortetracycline hydrochloride, oxytetra cycline hydrochloride, clindamycin hydrochloride, ethambutol hydrochloride, chlorohydrate hydrochloride Gentamicin, Kanamycin Sulfate, Lineomycin Hydrochloride, Methacycline Hydrochloride, Methenamine Hippurate, Methenamine Mandelate, minocycline hydrochloride, neomycin sulfate, netilmycin sulfate, paromomycin sulfate, streptomycin sulfate, tobramycin sulfate, miconazole hydrochloride, ketaconazole, amanfadine hydrochloride, amanfadine sulfate, oct ^ i ^ x ^ p ^ c ^ rqm ^ xylenol, nystatin, tolnaphtate, zinc pyrithione, clotrimazole, and combinations of '^^' ^ o

Antimicrobial agents are preferably included in concentrations ranging from about 0.1% to 10%, more preferably from about 1% to 5%, by weight of the personal cleansing composition.

J) Sunscreen assets

Non-exhaustive examples of sunscreen, organic or inorganic actives for use in the present invention are described below. Inorganic sunscreens useful for use in the present invention include metal oxides such as titanium dioxide with an average primary particle size of approximately 15 to 100 nm, zinc oxide with an average primary particle size of approximately 15 to 100 nm. 150 nm, zirconium oxide with a primary particle size of about 15 to 150 nm, iron oxide with an average primary particle size of 15 to 500 nm, and combinations of these.

The concentration of the sunscreen assets to use in the composition preferably ranges from 0.1% to 20%, typically from 0.5% to 10%, by weight of the composition. The exact amounts of sunscreen assets will vary depending on the sunscreen (s) chosen and the desired sun protection factor (SPF).

A wide variety of conventional active organic sunscreens are, furthermore, suitable for use in the present invention, the non-limiting examples of which include p-aminobenzoic acid, its salts and derivatives (ethyl, butyl butyl esters; p-dimethylaminobenzoic acid ); anthranilates (ie o-amino36 benzoates; methyl, menthyl, phenyl, benzyl, phenylethyl esters, jpn ^^, cyclohexenyl); salicylates (amyl esters, phenyl octyl, benzyl, memjfoygi ^ riip / ^ fe ^^

INDUSTRIAL pro-pylene glycol); cinnamic acid derivatives (menthyl and benzyl esters, α-phenyl cinnamonitrile; butyl cinnamoyl pyruvate); dihydroxycinnamic acid derivatives (umbelliferone, methylumbelliferone, methylacetoumbelliferone); trihydroxy-cinnamic acid derivatives (esculetin, methylsculetine, daphnetin, and the glucosides, scullna and daphnna); hydrocarbons (dlfenllbutadleno, stilbene); dlbenzalacetone and benzalacetophenone; naphtholsulfonates (sodium salts of 2-naphthol-3,6-disulfonic acids and 2-naphthol-6,8-disulfonic acids); di-hydroxynaphthoic acid and its salts; o- and phidroxybiphenyldisulfonates; coumarin derivatives (7-hydroxy, 7-methyl, 3-phenyl); diazoles (2-acetyl-3-bromoindazole, phenyl benzoxazole, methyl naphthoxazole, various aryl benzothiazoles); quinine salts (bisulfate, sulfate, chloride, oleate, and tannate); quinoline derivatives (8-hydroxyquinoline, 2-phenylquinoline salts); hydroxyl- or methoxysubstituted benzophenones; uric and violuric acids; tannic acid and its derivatives (p. eg, hexaethyl ether); (butyl carbotol) (6-propyl piperonyl) ether; hydroquinone; benzophenones (oxybenzene, sulisobenzone, dioxybenzone, benzoresorcinol, 2,2 ', 4,4'-tetrahydroxybenzophenone, 2,2'-dihydroxy-4,4'-dlmethoxylbenzophenone, octabenzone; 4-isopropyldibenzoylmethane; butylmethoxidine; (4'methylbenzylidene bornan-2-one), terephthalylidene dicamphor sulfonic acid and 4-isopropyl-dibenzoylmethane. Among these sunscreens are preferred 2-ethylhexyl-pmethoxycinnamate (commercially available as PARSOL MCX), 4,4'-t-butyl methoxydibenzoylmethane (commercially available as PARSOL 1789), 2-hydroxy-4methoxybenzophenone, octyldimethyl-p-aminobenzoic acid, digaloyltrioleate, 2,2-dihydroxy-4methoxybenzophenone, ethyl-4- (b¡s (hydroxypropyl)) amynobenzoate, 2-ethylhexyl-2-cyano-3,3-diphenyl acrylate, 2-ethylhexyl salicylate, Glyceryl p-aminobenzoate, Salicylate

3,3,5-tri-methylcyclohexyl, methylanthranilate, aminobenzoate acid, 2-ethylhexyl-p-dimethyl-aminobenzoate, p-dimethyl-aminobenzoic acid 2- ^ eftiTbenbi.

*. MEXICAN INSTITUTE. D * The PkCPtEDAD

INDUSTRIAL or

<img file="MX339063B_D0031.tif" />

and sulfonic, 2- (p-dimethylaminophenyl) -5-sulfonicobenzoxazoic acid, octocrylene combinations of these.

K) Solid particles

The composition of the present invention can comprise a solid particle. Non-limiting examples of solid particles include: interference pigment, multi-layer pigment, metal particle, liquid and solid crystals, or combinations thereof.

An interference pigment is a pearl luster pigment that is prepared by coating the surface of a particulate substrate material with a thin film. The particulate substrate material is generally in the form of a platelet. The thin film is a transparent or semi-transparent material that has a high refractive index. Material having a high refractive index exhibits a pearlescent luster resulting from the interference action between reflective light and incident light from the contact surface between the plate substrate and the coating layer and the reflectance of incident light from the surface of the coating layer. In order from least to most preferred, multi-phase personal care compositions comprise up to about 20 percent, up to about 10 percent, up to about 7 percent, and up to about 5 percent interference pigments by weight of the composition . In order from least to most preferred, multi-phase personal care compositions comprise more than about 0.1 percent, more than about 0.2 percent, more than about 0.5 percent, and more than about 1 percent of interference pigments. by weight of the composition. When the * pigment is applied v it is rinsed as described in the adhesive tape strip method ^^^ dÉ ^ i ^^ U ^ * ^

OF THE PROPERTY

INDUSTRIAL --— pigment deposition as described in copendierite application with serial number 60 / 469,075 filed on May 8, 2003, the pigment deposited on the skin is preferably at least 0.5 pg / cm2, with greater preference, at least 1 pg / cm2, and even more preferably, at least 5 pg / cm2.

In one embodiment of the present invention, the surface of the Interference pigment is hydrophobic or hydrophobically modified. The particle contact angle test, as described in application serial number 60 / 469,075 filed on May 8, 2003, is used to determine the contact angle of the interference pigments. The greater the contact angle, the greater the hydrophobicity of the interference pigment. The contact angle of the interference pigment of the present invention is at least 60 degrees, more preferably, greater than 80 degrees, even more preferably, greater than 100 degrees, still more preferably, greater than 100 degrees. Hydrophobically modified interference pigment, or HMIP, enables its own entrapment within phases and increased deposition of HMIP. In order from least to greatest preference, the ratio of the HMIP to a phase varies from 1: 1 to approximately 1:70, from 1: 2 to approximately 1:50, from 1: 3 to approximately 1:40 and from 1: 7 to approximately

1:35.

In one embodiment of the present invention, HMIPs are preferably trapped in the beneficial phase. For this it is necessary that the particle size of the beneficial phase is, generally, greater than the HMIP. In a preferred embodiment of the invention, the beneficial phase particles contain only a reduced amount of HMIP per beneficial particle. Preferably, that number is less than 20, more preferably less than 10 and most preferably less than 5. These parameters, the relative size of those relative to HMIP, and the approximate number of HMIP particles per beneficial particle can be determined by visual inspection with light microscopy.

The HMIP and the beneficial phase can be mixed into the composition through a premix or separately. When added separately, the hydrophobic pigments partition in the beneficial phase during the formulation process. The HMIP of the present invention preferably has a hydrophobic coating comprising up to about 20 percent, more preferably, up to about 15 percent, and even more preferably, up to about 10 percent by total particle weight. The HMIP of the present invention preferably has a hydrophobic coating comprising at least about 0.1 percent, more preferably, at least about 0.5 percent by weight, and even more preferably, at least about 1 percent by total weight of the particle. Non-limiting examples of hydrophobic surface treatments useful in the present invention include silicones, acrylate and silicone copolymers, acrylate polymers, alkylsilane, isopropyl titanium triisoestearate, sodium stearate, magnesium myristate, perfluoroalcohol phosphate, perfluoropolymethyl isopropyl ether, lecithin carnauba wax, polyethylene, chitosan, lauroyl Usina, vegetable lipid extracts and mixtures of these, preferably silicones, silanes and stearates. Some manufacturers of surface treatments are US Cosmetics, KOBO Products Inc. and Cardre Inc.

oenettcas./Cor „^ INSTITUTO MEXICANO ..

OF PROPERTY C * ·. » INDUSTRIAL

<img file="MX339063B_D0032.tif" />

L) Anti-dandruff agents

The shampoo compositions of the present invention may additionally contain an anti-dandruff agent. Suitable non-limiting examples of anti-dandruff agents include: pyridination salts, specifically the zinc salt of 1-hydroxy-2 ^ ¡rid¡nat¡ona iMfií · '(known as "zinc pyridination" or "ZPT") , azoles, setenium sulfide, uaobifee patíiGulá '

FROM INDUSTRIAL PROPERTY keratolytic acid, salicylic acid, octopirox (pyroctone olamine), coal tar, and combinations thereof. In one aspect, anti-dandruff agents are typically pyridination salts. These anti-dandruff agents must be physically and chemically compatible with the essential components of the composition and must not unduly affect the stability, aesthetic appearance or performance of the product.

Pyridination anti-dandruff agents are described, for example, in US Pat. USA no. 2,809,971, US Pat. USA no. 3,236,733, US Pat. USA no. 3,753,196, US Pat. USA no. 3,761,418, US Pat. USA no. 4,345,080, US Pat. USA no. 4,323,683, US Pat. USA no. 4,379,753 and US Pat. USA no. 4,470,982. It is contemplated that when ZPT is used as the anti-dandruff particulate in the compositions in the present invention, hair growth or regrowth may be stimulated or regulated, or both, or hair loss may be reduced or inhibited, or that hair may have a thicker or more abundant appearance.

Optional ingredients

Although not essential for the purposes of the present invention, the non-limiting list of materials, in addition to those previously described, optional materials illustrated hereinafter are suitable for use in the personal care composition, and may be it is desirable to incorporate them in certain modalities, for example, to help or improve cleaning performance, for skin treatment, or to modify the aesthetics of the composition for personal care, as is the case with perfumes, dyes, dyes or the like. Optional materials useful in the products of the present invention are classified by category or described by their benefits.

<img file="MX339063B_D0033.tif" />

therapeutic, or by its postulated form of action or function. Without erpbafgoj ^^^^ nC. Industrial that the active materials and other materials useful in the present invention may, in some cases, provide more than one cosmetic or therapeutic benefit or function or act by more than one mechanism of action. Therefore, the classifications of the present invention are made for convenience reasons and are not intended to limit an ingredient to the particularly designated application or listed applications. The exact nature of these optional materials and their incorporation concentrations will depend on the physical form of the composition and the nature of the cleaning operation for which it will be used. Optional materials are usually formulated to less than about 6%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, less than about 1%, less than about 0.5% , less than about 0.25%, less than about 0.1%, less than about 0.01%, less than about 0.005% of the personal care composition.

To further improve stability under stress conditions such as temperature and vibration, it is preferred to adjust the densities of the separated phases so that they are practically the same. To achieve this, low density microspheres can be added to one or more phases of the personal care composition, preferably the structured surfactant phase. The personal care composition comprising low density microspheres is described in a patent application published on May 13, 2004 under US patent publication. USA no. 2004 / 0092415A1 entitled "Liquid Compositions without Extras for Personal Cleaning Containing One Phase for Cleaning and a Separate Phase with Enhanced Stability," filed October 31, 2003 by Focht, et al.

Other optional non-limiting ingredients that ^s®J³J ^ⁿp ^^rpersonal care composition of the present invention can EXEX ^ Wic ^ Z ^ Q ^ optional beneficial component selected from the group consisting of thickening agents; preservatives; antimicrobials; fragrances; chelators (eg, such as those described in US Patent No. 5,487,884 to Bisset et al.); kidnappers; vitamins (eg, Retinol); vitamin derivatives (eg. eg, tocopheryl acetate, niacinamide, panthenol); Sunscreens; desquamation assets (eg, such as those described in US Patent Nos. 5,681,852 and 5,652,228 to Bisset); anti-wrinkle / anti-atrophy actives (eg, N-acetyl derivatives, thiols, hydroxyl acids, phenol); antioxidants (eg, ascorbic acid derivatives, tocophenol), sedative / skin healing agents (eg. eg, derivatives of pantenoic acid, aloe, allantoin); skin lightening agents (eg, kojic acid derivatives, arbutin, ascorbic acid), skin tanning agents (eg, dihydroxyacetone); anti-acne medications; essential oils; skin sensation agents; pigments; colorants; pearling agents; interference pigments (eg, such as those described in US Pat.

USA no. 6,395,691 issued to Liang Sheng Tsaur, US Patent USA no. 6,645,511 issued to Aronson et al .; US patent USA no. 6,759,376 issued to Zhang et al., US Pat. USA no. 6,780,826 issued to Zhang et al.) Particles (eg talc, kaolin, mica, smectite clay, cellulose powder, polysiloxane, silicas, carbonates, titanium dioxide, polyethylene beads), hydrophobically modified non-platelet particles (p. For example, titanium dioxide and other hydrophobically modified materials described in the joint property patent application published on August 17, 2006 with the no. Publication 2006 / 0182699A entitled "Personal Care Compositions Containing Hydrophobically Modified Non-platelet Particles" filed February 15, 2005 by Taylor et al.), and mixtures thereof. In one aspect, the personal care composition J^orí · comprise from approximately 0.1% to approximately 4%, in personal composition of multiple phase of hydrophobically modified titanium dioxide.

Other optional ingredients are typically those materials approved for use in cosmetics and described in the CTFA Cosmetic Ingredient Handbook, Second Edition, 1988, 1992.

Test methods

The present invention uses a series of test methods to determine various structure metrics. The methodology for these tests and associated examples are illustrated below.

Determine the degree of complex formation.

The degree of complex formation for each PRM = [Total fragrance in BCD free fragrance] / [Total fragrance] * 100%

Determination of the total fragrance in BCD g of the sample was placed in a 125 ml square bottle with 50 ml (39.25 g) of acetone, the sample was heated at 70 C for 5 hours and stirred, then, for one hour before seep and injection. Analyzed using gas chromatography - mass spectroscopy.

Diphenyl oxide was used as the internal standard (800 mg in 1 liter of acetone).

Determination of fragrance not completed in BCD

0.2 g of sample was gently placed in a bottle with 10 ml of THF for 10 inversions.

<img file="MX339063B_D0034.tif" />

MjPRC INDUSTRIAL

Determination of the degree of retention of BCD-PRM complex in a pure liquid body soap product

The BCD-PRM complex was prepared where the degree of complex formation is greater than 90%.

Control product: Liquid body soap with a free fragrance

Test Product: The same liquid body soap with a total equivalent of fragrance coming entirely from a BCD-PRM complex

The degree of complex retention is determined by the average ratio of the void concentration of all PRMs prior to the test product to the control product.

If the ratio is one, the degree of complex retention is zero since all PRMs are released from the BCD and the liquid body soap test product behaves the same as the control product.

If the ratio is zero, the degree of complex retention is one since all the PRMs bind to the BCD, there are no PRMs released from the product.

Gas chromatography / mass spectrometry ("GC-MS") solid phase microextraction (SPME) is used to measure the amount of perfume raw material in the empty space of the products. 1.0 grams of the control and test product was placed in clean 20 ml empty space flasks and allowed to equilibrate for at least 2 hours at room temperature.

The samples are then analyzed using the MPS2-SMPE-GC-MS analysis system (GC-02001-0153, MSD-02001-0154, MPS2-02001-0155).

Apparatus:

-JL _ MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY

<img file="MX339063B_D0035.tif" />

one. 20 ml empty space bottle

2. Chronometer.

3. Gas Chromatograph (GC): Agilent, Model 6890, with a CIS-4 injector (Gerstel, Mulhelm, Germany) and MPS-2 and TDU (thermal desorption unit) autosampler . For SPME analysis, the split / split injector (not the CIS-4 injector) was used.

Four. GC column: J&amp;W DB-5 MS, 30 M x 0.25 mm ID, 1.0 pm film thickness obtained from J&amp;W Scientific of Folsom, California, United States.

5. Carrier gas, helium, 1.5 ml / min flow rate.

6. The injector liner is a special SPME liner (0.75mm ID) from Supelco.

7. The detector is a model 5973 mass selective detector obtained from Agilent Technologies, Inc., Wilmington, DE, USA. USA It has a source temperature of approximately 230 ° C, and an MS Quad temperature of approximately 150 ° C.

Analysis procedure:

one. The sample is transferred to the appropriate sample tray and the SPME-GC-MS analysis is continued.

2. The loading sequence and analysis of the sample begins. At this stage, the sample is allowed to equilibrate for at least two hours in the autosampler tray and is then obtained in the tray. The SPME fiber unit is DVB / CAR / PDMS (50/30 um, ga, 1 cm long). The sampling time is 5 minutes.

3. The injector temperature is 260 ° C.

Four. The GC-MS analysis series is then started. The desorption time is 5 minutes.

5. The following temperature program is used:

i) an initial temperature of approximately 50 ° C that is maintained for 3 minutes, ii) That increases the initial temperature at a rate of approximately 6 ° C / min until it reaches a temperature of approximately 250 ° C, then 25 ° C / min at 275 ° C, held at about 275 ° C for

4.67 minutes.

6. Perfume compounds are identified using the John Wiley &amp; Sons and National Institute of Standards and Technology (NIST) Spectral MS libraries, purchased and licensed from Hewlett Packard.

7. Chromatographic peaks for specific ions are integrated with Chemstation software obtained from Agilent Technologies, Inc., Wilmington, DE, USA. USA

8. The ratio of each PRM is taken as the ratio of the peak area for the perfume raw material in product A relative to product B

9. The average ratio is calculated as the average obtained in stage 8 for all subjects

<img file="MX339063B_D0036.tif" />

Determine the average concentration ratio of diluted or net void space for all values ​​(“ARPON”) of perfume products

The GC-MS gap is used to measure the perfume differences in the gap of diluted product (1:10 dilution of water) relative to the net gap. Table 2 illustrates the results of the ARDON test.

grams of product in 20 ml of HS bottle

<td>Table 2</td><td>Sample Description</td><td>BCD or BCD Perfume</td><td>ARDON</td>

<td></td><td></td><td></td><td></td>

<td> 1</td><td>Liquid body soap structure with BCD complex</td><td>Yes</td><td> 179 % ± 25 %</td>

<td> 2</td><td>Structure of liquid body soap with perfume free</td><td>No</td><td> 117% ±12%</td>

<td> 3</td><td>1 * Commercially Available Liquid Body Soap from 1 * Irish Spring Liquid Body Soap</td><td>No</td><td> 102 %</td>

<td> 4</td><td>2 * Commercially Available Liquid Body Soap Dial Liquid Soap</td><td>No</td><td> 86%</td>

Zero Shear Viscosity Methods v Youna Modulus

The zero shear viscosity of a material that is a phase or composition of the present invention can be measured prior to combining into the composition, after preparing a composition, or first separating a phase or component from a composition by means suitable physical separation, such separation.

such as centrifugation, pipetting, mechanical cutting, rinsing, filtering

MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY

A controlled effort rheometer, such as the TA rheometer, is used

<img file="MX339063B_D0037.tif" />

Instruments AR2000, in order to determine the zero shear viscosity. The determination is made at 25 ° C with the parallel plate measurement system 4 cm in diameter and with a space of 1 mm. The geometry has a shear stress factor of 79580 m-3 to convert the torque obtained into effort. Toothed plates can be used to obtain consistent results when an error occurs.

First the material is placed on the rheometer base plate, the measurement geometry (top plate) is moved at the position 1.1 mm above the base plate. Surplus material is removed at the edge of the geometry by scraping after freezing the geometry. The geometry is then moved to the target position 1mm above the base plate and a pause of approximately 2 minutes is allowed to allow the load stresses to relax. This loading procedure ensures that no tangential stress is loaded at the beginning of the measurement, which could influence the results obtained. If the material contains particles discernible with the naked eye or by touch (globules, e.g. eg) that are larger than about 150 microns in numerical average diameter, the gap established between the base plate and the top plate is increased to the smallest of 4 mm or eight times the diameter of the particle diameter at the 95th percentile of the volume. If the phase does not contain particles larger than 5 mm in some dimension, the particles are removed before measurement.

The measurement is made by applying a continuous increase in shear stress from 0.1 Pa to 1,000 Pa during a time interval of 4 minutes per

<img file="MX339063B_D0038.tif" />

means of using a logarithmic progression, that is, points d uniformly on a logarithmic scale. Thirty (30) punfos are obtained ^ eineclici!

decade of increased effort. If the measurement result is eeompotor, for example, yes. it is observed that the material flows from the space, the obtained results are evaluated with the incomplete data points excluded. If there are insufficient points to obtain an exact measurement, the measurement is repeated with a greater number of sample points.

Young's modulus (Pa) is obtained by graphing the stress (Pa) compared to the stress (without units) and by obtaining the slope of the regression line of the initial linear region between stress vs. stress, which typically occurs in the region below about 4% of stress. If the relationship is not linear, the slope of the linear regression line below 2% of the stress is taken as Young's Modulus (Pa), using the unitless stress.

Zero shear viscosity is obtained by taking a first average value of the viscosity in Pascal per seconds (Pa-sec) for the viscosity data obtained between and including 0.1 Pa and the point where the viscosity begins to decline abruptly. After taking the first average viscosity, all viscosity values ​​greater than 5 times the first average value and less than 0.2x the average value are excluded and a second average viscosity value is obtained from the same viscosity data, and excluded the indicated data points. The second average viscosity obtained is the zero cut viscosity.

The compositions of the present invention have a zero shear viscosity of at least about 100 Pa-s, alternatively at least about 300 Pa-s, alternatively at least about 500 Pa-s, alternatively at least about 1000 Pa-s , alternatively, at least approximately 1500 Pa-s, alternatively, at least approximately J ^ jitj ^ y ^ g ^^^

The compositions of the present invention have 'INDUSTRIAL *' &lt;

at least about 2 Pa, alternatively, at least about 5 Pa, _ alternatively, at least about 10 Pa, alternatively, at least about 20 Pa, alternatively, at least about 40 Pa, alternatively, at least about 50 Pa, alternatively, at minus approximately 75 Pa.

Ultracentrifuation method

The ultracentrlfugation method is a physical method that is used to determine the structure in a composition or a subset of a composition. The method is also used to determine the rate at which a structured surfactant composition dissolves with dilution to present effective amounts of surfactant to the cleaning environment near surfaces.

A composition is ultracentrifugally separated into separate, but distinguishable, layers. The multiphase personal care composition of the present invention can have multiple distinguishable layers (eg, a structured surfactant layer, and a beneficial layer).

First, approximately 4 grams of the composition is dispensed into a Beckman centrifuge tube (11x60mm) to fill the tube. The composition is then diluted to a dilution level of 10% by using 90% of the composition and 10% DI water by using a suitable mixer and the same amount of composition is supplied in a tube company centrifuge. The dilution of the composition is continued and the tubes are filled in the same manner until a dilution level of 60% is obtained for the composition by using% of the composition with 60% DI water. The tuíjsj ^^ pfrju an ultracentrifuge (Beckman model L8-M or equivalent) pdF is placed^sfí§ ^ iOiéíYour sling rotor and ultracentrifuge by using the following conditions:

• - -t m. i *¹ "me

50,000 rpm, 2 hours and 40 ° C.

The relative phase volumes of the phases of the composition are measured by measuring the height of each layer using an electronic digital caliper (within 0.01 mm). Those with experience in the field identify the layers using physical observation techniques paired with chemical identification if necessary. For example, the structured surfactant layer is identified by transmission electron microscope (TEM), polarized light microscopy, and / or X-ray diffraction for the present invention as a structured lamellar phase comprising multilamellar vesicles, and the layer Hydrophobic benefit is identified by its low moisture content (less than 10% water measured by Karl Fischer titration). Total height H_to all materials in the ultracentrifuge tube are measured and included. The height of each layer is then measured from the bottom of the centrifuge tube to the top of the layer, and the span of each layer is determined algebraically by subtraction. The beneficial layer can comprise multiple layers if the beneficial phase has more than one component that can cause the phase to divide into the liquid and waxy layers, or if there is more than one beneficial component. If the charitable phase is divided, the sum of the charitable layers measured is the height of the charitable layer, H_bGenerally, a hydrophobic beneficial layer, when present, is on top of the centrifuge tube.

The surfactant phase can comprise several layers or a single layer, H_c. In addition, there may be a clear, unstructured, isotropic micellar layer at or near the bottom of the ultracentrifuge tube. Layers immediately

<img file="MX339063B_D0039.tif" />

Above the isotropic phase, they generally comprise higher concentrations of

TIVI Ρ Ϊ surfactant with higher ordered structures (such as

INDUSTRIAL PROPERTY structured layers are often opaque to the naked eye, or translucent, or clear.

There may be several structured layers present, in which case H_c it is the sum of the individual structured layers. If any type of polymer-surfactant phase is present, it is considered a structured phase and is included in the measurement of H_c. The sum of the aqueous phases is H_s.

Finally, the volume ratio of the structured domain is calculated as follows:

Structured domain volume ratio = H_c / H_s *100 %

If no beneficial phase is present, the total height is used as the surfactant layer height, H_s= H_to. For the present invention, the volume ratio of the structured domain is% of the lamellar phase. Measurement is made for each prepared and centrifuged dilution, i.e. the volume ratio of the structured domain is determined for the composition, and for the 90%, 80%, 70% and 60% dilutions prepared as indicated above.

The highest amount of dilution (i.e. the lowest dilution level) where the composition maintains at least 95% lamellar phase is an indicator of the amount of structure for compositions that have different values ​​of n for

STnS.

In one embodiment, the higher dilution where the composition has at least 95% lamellar phase is greater than about 15%, alternatively, greater than about 25%, alternatively, greater than about

<img file="MX339063B_D0040.tif" />

%.

In one embodiment, the composition has a structured ratio of at least about 40%, alternatively, at least about 45%, alternatively, at least about 50%, alternatively, at least about 55%, alternatively, at least about 60%, alternatively , at least about 65%, alternatively, at least about 75%, alternatively, at least about 80%, alternatively, greater than about 90% by volume of the aqueous surfactant composition.

Ultracentrlfuqaclón dilution method

The dilution ultracentrifugation method is a physical method used to determine the amount of structure in a composition at a certain point in its dilution profile, which refers to the composition's ability to foam. The dilution ultracentrifugation method uses the results of the ultracentrifugation method at the 50% dilution point. When consumers use the surfactant compositions with an instrument such as a towel or a bean bag, typically, about 10 ml of the composition is dispensed into the instrument containing about 10 ml of water in it. Consumers shake to foam, requiring the composition to dissolve rapidly at this dilution force. The ability of the structured surfactant compositions to dissolve in the 50% dilution is measured by the method.

The method is identical in all its details to the ultracentrifugation method. The result in the 50% dilution is obtained for a composition and is expressed as the volume of the lamellar phase diluted to 50%.

The results of the dilution ultracentrifugation method are compared with the results obtained for the dissolution rate test for the compositions of the present invention comprising STnS, and

FROM THE INDUSTRIAL PROPERTY the high structure and the reduced foam, and vice versa, which give rise to the improved stability and the aesthetics of use within a narrower range of values ​​of STnS. The STOS composition of Example 4 which is relatively unstructured, has a lower structure after dilution, but is not suitable for the purposes of a structured surfactant composition due to its inability to supply the required stabilization to a composition based on its rheology. The ST3S composition of Example 1 has sufficient structure and rapidly dilutes micellar surfactants useful for foaming and cleansers, but disadvantageously these ST3S compositions cannot be easily formulated into compositions comprising reduced levels of surfactant; they will always be expensive, inefficient, less environmentally preferred, and less gentle. The ST1S composition of Example 3 has a 50% dilute lamellar phase volume of 100%, which will result in poor foam and cleaning characteristics in many modes of use. The ST2S composition of Example 2 demonstrates versatility since at a high degree of structure it still dilutes sufficiently to provide a good foaming result, lather capacity supported by its volume value of lamellar phase diluted to 50% of 70% . ST2S compositions can be prepared at reduced surfactant levels, for example 15%, or 12%, or 10% or 8%, or even 6% surfactant and retain many of the preferred characteristics of the present invention.

In an embodiment of the present invention, the volume of the lamellar phase diluted to 50% for a composition of the present invention is less than about 90%, alternatively, less than about 80%, alternatively, less than 75%.

<img file="MX339063B_D0041.tif" />

j

Dissolution rate method J j \ / JJ? J

MEXICAN INSTITUTE

Structured compositions are prone to loss.ⁱfetus, '⁴As a result, poor foaming and cleaning characteristics can result. The slow dissolution of structured surfactant phases is largely behind the development of the “Puff” instrument many years ago, a stirring instrument that supports dissolution, foaming and cleaning. Foaming and cleaning result from the ability of aqueous surfactant molecules to diffuse and stabilize air interfaces and soil surfaces. When surfactants remain enclosed in lamellar structures or other organized structures, they are not able to diffuse into the aqueous phase and therefore must first be dissolved as individual monomers and surfactant micelles in order to be effective. Dilution and agitation support dissolution during use. The dissolution rate method measures the extent of dissolution of a surfactant composition in water.

A straight-walled glass vase with an inner diameter (Id) of 63 mm and an inner height of 87 mm is obtained, eg. eg Pyrex 250 mi (# 1000) which are widely available. 150 grams of distilled water is poured into the glass at room temperature (75 ° F). A Teflon® coated magnetic stir bar is added to the beaker. The stir bar is nominally 1.5 inches long x 5/16 inches in diameter and octagonal in shape viewed from the end and has a molded 1/16 inch wide pivot ring around the center where the diameter increases to approximately 0.35 inches, Spinbar ® stir bars are available from Slgma Aldrlch Corp. around the world which includes Milwaukee,

Wl, USA USA and at www.sigmaaldrich.com.

The initial conductivity of water is measured and recorded by using a conductivity meter, eg. eg, a Mettler-Toledo SevenMulti meter with lnLab740 probe, and record the value. The conductivity of about 2 microSemens / cm (uS / cm) or less for 'industrial

<img file="MX339063B_D0042.tif" />

dissolved solids present. The conductivity probe is removed from the water and the beaker is placed on a digitally controlled laboratory shaker, eg available Ika ® Werke RET Control-vise, e.g. Eg, from DivTech Equlpment Co, Cincinnati, OH, USA. USA The glass is centered on the stirrer and the stirrer is turned on to obtain a constant rotational speed of 500 rpm, a vortex is established in the water that is approximately 3 cm deep from the highest point of water at the edge of the glass at lowest point of air in the center of the vortex. Observe the vortex from above to ensure it is centered in the glass, and the magnetic stir bar centered in the center of the vortex.

Obtain a surfactant phase and fill it into a 1 ml syringe without trapping air. The syringe has a diameter of approximately 1.9 mm at the tip (eg, BD 1 ml tuberculin slip tip, Becton, Dlckinson and Co., Franklln Lakes, NJ, USA). Inject the surfactant phase in a constant stream into the top of the glass of water near the edge of the glass but without touching the edge of the glass. The composition should be injected in about 1 second. An automatic watch is wound and the composition is allowed to stir for 30 seconds.

The stirrer is turned off. The conductivity probe is inserted into the water in a location away from undissolved solids. The measurement is allowed to stabilize and a conductivity reading is taken and the conductivity is recorded.

The agitator turns on again. The automatic clock is restarted when the digital reading passes 250 rpm. After an additional 30 seconds of elapsed time, the stirrer is turned off and the conductivity is measured in the same manner as above. Conductivity is recorded.

<img file="MX339063B_D0043.tif" />

The agitator turns on again. Jut ^ | tijd Ja watch restarts

MEXICAN INSTITUTE OF PROPERTY digital reading pass 250 rpm. After an additional 60 seconds of transfer time, the stirrer is turned off and the conductivity is measured in the same manner as above. I know. record conductivity.

The probe is removed from the water without altering the remaining solids. The glass is covered with a suitable waterproof lid, for example a plastic wrap and a rubber band. Shake the beaker vigorously for approximately 30 seconds to dissolve the remaining solids, using a vortex shaker, additionally if necessary.

The glass is uncapped, the conductivity is measured and the value is recorded as the final conductivity.

The% dissolution at each time point is calculated according to the following equation:

Dissolution% = 100% x (conductivity - initial water conductivity) (final conductivity - initial water conductivity)

The measurement is repeated if needed to obtain a representative average value.

At the 60 second time point, the compositions of the present invention have a% dissolution of at least about 60%, alternatively, at least about 70%, alternatively, at least about 80%. At the 120 second time point, the compositions of the present invention have a% dissolution of at least about 80%, alternatively, at least about 85%, alternatively, at least about 90%, alternatively, at least about ^ eij ^ ^^ o ^.

MEXICAN INSTITUTE OF PROPERTY

INDUSTRIAL

Third phase method to determine the stability of the structured surfactant

The "third phase" method is used to determine the stability of the structured surfactant phase in a personal cleansing composition. The method involves putting the personal care compositions at 50 ° C for 10 days for rapid aging. After rapid aging, approximately 4 grams of the composition is transferred to a Beckman centrifuge tube (11x60mm). The centrifuge tube is placed in a Beckman LE-80 Ultracentrifuge and operated under the following conditions: 50,000 rpm; 2 hours, and at 40 ° C.

After ultracentrifugation, the volume of the third phase is determined by measuring the height of the various surfactant phases with an electronic digital caliper (within 0.01 mm).

The top layer is the hydrophobic beneficial phase layer (hydrocarbons or soybean oil, etc.). The layers below the hydrophobic beneficial phase layers containing surfactant / water are determined as follows: H_tois the height of all layers containing surfactant / water and H_b is the height of the clear “third phase” layer just below the hydrophobic beneficial phase layer. It is important to record the readings within 30 minutes after the ultracentrifugation has finished to reduce the migration of the material through the different layers. The volume of the third phase is calculated as follows:% of the volume of the third phase = Hu / H_to *100 %

Preferably, the structured surfactant composition comprises less than 10% of the "third phase" volume after the rapid aging stability protocol. More preferably, the

INSTITUTO Ml'TCANO OE LA TRCriIC.O structured comprises less than 5% of the volume of the "third IS ^ 'tlespbes ^ Jel rapid aging stability protocol. With — mayen — preference,¹ the structured surfactant composition comprises less than 2% of the "third phase" volume after the rapid aging stability protocol. Still more preferably, the structured surfactant composition comprises less than 1% of the "third phase" volume after the rapid aging protocol. Most preferably, the structured surfactant composition comprises approximately 0% by volume of the "third phase" after the rapid aging protocol.

The dimensions and values ​​described in the present description should not be understood as strictly limited to the exact numerical values ​​mentioned. Instead, unless otherwise specified, each of those dimensions will refer to both the mentioned value and a functionally equivalent range comprising that value. For example, a dimension expressed as "40mm" will be understood as "approximately 40mm".

It shall be understood that each maximum numerical limitation given in this specification will include any lower numerical limitation, as if such lower numerical limitations had been explicitly noted herein. Any minimum numerical limit given in this specification shall include any greater numerical limit, as if the greater numerical limits had been explicitly noted herein. Any numerical ranges given throughout this specification will include each minor numerical range found in said broader numerical range, as if such minor numerical ranges are expressly indicated in the present invention.

All documents cited in the description of | ali | ^

INSTITUTO MEXICANO incorporate, in the relevant industry, as a reference in the preá £ fóá? S $ i ¿^ ¡peÍ

<img file="MX339063B_D0044.tif" />

Quotation from any document should not be construed as an admission Ha representing a prior subject with respect to the present invention. To the extent that any meaning or definition of a term in this written document contradicts any meaning or definition of the term in a document incorporated by reference, the meaning or definition assigned to the term in this written document shall govern.

Although particular embodiments of the present invention have been illustrated and described, it will be apparent to those skilled in the art that various changes and modifications can be made without departing from the spirit and scope of the invention. Therefore, the appended claims are intended to cover all modifications and changes that are within the scope of this invention.

<img file="MX339063B_D0045.tif" />

MEXICAN INSTITUTE

Dt THE PROPERTY

INDUSTRIAL